Monkeypox vaccine safety under the microscope in congo study

NCT ID NCT05734508

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study monitored the safety of the MVA-BN (Jynneos) vaccine in 500 adults at high risk for monkeypox in the Democratic Republic of the Congo. Participants received two doses of the vaccine and were followed for up to 28 days after their last dose. The main goal was to track any serious or minor side effects that occurred shortly after vaccination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MVA-BN (Jynneos) vaccine
What this could lead to: If the vaccine is shown to be safe, it could support its use to protect people at high risk for monkeypox.
What could go wrong: This study only looked at safety, not how well the vaccine prevents infection. It was also small and limited to a specific group of adults.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monkeypox prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MONKEYPOX

Contacts and locations

Locations

Institut National de Rescherche Biomédicale (INRB)

Kinshasa, Democratic Republic of the Congo
L'Hôpital Général de Référence de Kole

Kole, Democratic Republic of the Congo
L'Hôpital Général de Référence de Tunda

Tunda, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.